Spots Global Cancer Trial Database for leukemia, myelomonocytic, chronic
Every month we try and update this database with for leukemia, myelomonocytic, chronic cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS | NCT00025662 | Graft vs Host D... Myelodysplastic... Leukemia Leukemia, Myelo... Leukemia, Myelo... Leukemia, Lymph... Lymphoma Lymphoma, Mantl... Lymphoma, Non-H... Hodgkin Disease | RFT5-SMPT-dgA Isolex system | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| A Study of HDC/IL-2 Treatment in Chronic Myelomonocytic Leukemia (CMML) | NCT03040401 | Leukemia, Myelo... | Cohort 1, Ceple... Cohort 2, Ceple... Cohort 3, Ceple... | 18 Years - | Vastra Gotaland Region | |
| Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) | NCT04266301 | Myelodysplastic... Leukemia, Myelo... | Sabatolimab Azacitidine Placebo | 18 Years - | Novartis | |
| Volasertib in Combination With Azacitidine in Japanese Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia | NCT02201329 | Myelodysplastic... Leukemia, Myelo... | Azacitidine Volasertib | 20 Years - 80 Years | Boehringer Ingelheim | |
| Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma | NCT00761722 | Acute Myeloid L... Myelodysplastic... Lymphoma Multiple Myelom... Leukemia, Myelo... | azacitidine | 18 Years - | Celgene | |
| Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) | NCT04266301 | Myelodysplastic... Leukemia, Myelo... | Sabatolimab Azacitidine Placebo | 18 Years - | Novartis | |
| Efficacy Study of Revlimid® and Low Dose Continuously Administered Melphalan to Treat High Risk MDS | NCT00744536 | Myelodysplastic... Leukemia, Myelo... Angiogenesis | Lenalidomide an... | 18 Years - | Sunnybrook Health Sciences Centre | |
| Korean Post-marketing Surveillance for Sprycel® | NCT01464047 | Leukemia, Myelo... Leukemia-Lympho... | - | Bristol-Myers Squibb | ||
| Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED) | NCT00109538 | Myelodysplastic... Leukemia, Myelo... Myelodysplasia Myelomonocytic | Lonafarnib Placebo | 18 Years - | Merck Sharp & Dohme LLC | |
| Sorafenib in Myelodysplastic Syndrome | NCT00510289 | Myelodysplastic... Leukemia, Myelo... | Sorafenib | 18 Years - | Duke University | |
| Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED) | NCT00109538 | Myelodysplastic... Leukemia, Myelo... Myelodysplasia Myelomonocytic | Lonafarnib Placebo | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study of HDC/IL-2 Treatment in Chronic Myelomonocytic Leukemia (CMML) | NCT03040401 | Leukemia, Myelo... | Cohort 1, Ceple... Cohort 2, Ceple... Cohort 3, Ceple... | 18 Years - | Vastra Gotaland Region | |
| Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS | NCT00025662 | Graft vs Host D... Myelodysplastic... Leukemia Leukemia, Myelo... Leukemia, Myelo... Leukemia, Lymph... Lymphoma Lymphoma, Mantl... Lymphoma, Non-H... Hodgkin Disease | RFT5-SMPT-dgA Isolex system | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs | NCT02907359 | Myelodysplastic... Leukemia, Myelo... | Guadecitabine Treatment Choic... | 18 Years - | Astex Pharmaceuticals, Inc. | |
| Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid Leukemia | NCT02807272 | Leukemia, Myelo... | Tipifarnib | 18 Years - | Kura Oncology, Inc. | |
| Phase I Dose Escalation Trial of Volasertib in Combination With Azacitidine in Patients With MDS or CMML | NCT01957644 | Myelodysplastic... Leukemia, Myelo... | Azacitidine Volasertib | 18 Years - | Boehringer Ingelheim | |
| Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab. | NCT05201066 | Myelodysplastic... Leukemia, Myelo... | decitabine spartalizumab sabatolimab azacitidine venetoclax INQOVI (oral de... | 12 Years - 99 Years | Novartis | |
| A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems | NCT03814005 | Myelodysplastic... Leukemia, Myelo... Leukemia, Myelo... Renal Insuffici... Liver Disease Neoplasms | Azacitidine Pevonedistat Docetaxel Paclitaxel Carboplatin | 18 Years - | Takeda | |
| Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid Leukemia | NCT02807272 | Leukemia, Myelo... | Tipifarnib | 18 Years - | Kura Oncology, Inc. | |
| An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML) | NCT02610777 | Myelodysplastic... Leukemia, Myelo... Leukemia, Myelo... | Azacitidine Pevonedistat | 18 Years - | Takeda | |
| Myeloproliferative Neoplasms (MPNs) Patient Registry | NCT02760238 | Primary Myelofi... Polycythemia Ve... Essential Throm... Mastocytosis Leukemia, Myelo... Leukemia, Myelo... Chronic Eosinop... Myelodysplastic... Neoplasms Leukemia, Myelo... | Observational | - | University Health Network, Toronto | |
| Health Outcomes of Recently Diagnosed Myelodysplastic Syndrome (MDS)/Chronic Myelomonocytic Leukemia (CMML) Patients Depending on Treatment Strategy (Wait and See, Support, Active Treatment) | NCT02085798 | Myelodysplastic... Leukemia, Myelo... | Either Wait and... | 18 Years - | Celgene | |
| Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) | NCT00255346 | Acute Myeloid L... Myelodysplastic... Agnogenic Myelo... Myelofibrosis Hypereosinophil... Polycythemia Ve... Mastocytosis Leukemia, Myelo... | Dasatinib (BMS-... | 18 Years - | M.D. Anderson Cancer Center | |
| Myeloproliferative Neoplasms (MPNs) Patient Registry | NCT02760238 | Primary Myelofi... Polycythemia Ve... Essential Throm... Mastocytosis Leukemia, Myelo... Leukemia, Myelo... Chronic Eosinop... Myelodysplastic... Neoplasms Leukemia, Myelo... | Observational | - | University Health Network, Toronto | |
| A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes | NCT02841540 | Leukemia, Myelo... Myelodysplastic... Leukemia, Myelo... | H3B-8800 (RVT-2... | 18 Years - | Hemavant Sciences GmbH | |
| A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes | NCT02841540 | Leukemia, Myelo... Myelodysplastic... Leukemia, Myelo... | H3B-8800 (RVT-2... | 18 Years - | Hemavant Sciences GmbH | |
| Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) | NCT00255346 | Acute Myeloid L... Myelodysplastic... Agnogenic Myelo... Myelofibrosis Hypereosinophil... Polycythemia Ve... Mastocytosis Leukemia, Myelo... | Dasatinib (BMS-... | 18 Years - | M.D. Anderson Cancer Center | |
| An Observational Post Authorisation Study to Evaluate Safety and Efficacy in Patients Receiving Azacitidine in Daily Clinical Practice in the Netherlands | NCT02891551 | Myelodysplastic... Leukemia, Myelo... Leukemia, Myelo... | 18 Years - | Celgene | ||
| Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab. | NCT05201066 | Myelodysplastic... Leukemia, Myelo... | decitabine spartalizumab sabatolimab azacitidine venetoclax INQOVI (oral de... | 12 Years - 99 Years | Novartis | |
| Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) | NCT03268954 | Myelodysplastic... Leukemia, Myelo... Leukemia, Myelo... | Azacitidine Pevonedistat | 18 Years - | Takeda | |
| Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) | NCT00255346 | Acute Myeloid L... Myelodysplastic... Agnogenic Myelo... Myelofibrosis Hypereosinophil... Polycythemia Ve... Mastocytosis Leukemia, Myelo... | Dasatinib (BMS-... | 18 Years - | M.D. Anderson Cancer Center | |
| Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral Azacitidine | NCT01519011 | Myelodysplastic... Leukemia, Myelo... Leukemia, Myelo... | oral azacitidin... oral azacitidin... | 18 Years - | Celgene | |
| Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma | NCT00761722 | Acute Myeloid L... Myelodysplastic... Lymphoma Multiple Myelom... Leukemia, Myelo... | azacitidine | 18 Years - | Celgene | |
| Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED) | NCT00109538 | Myelodysplastic... Leukemia, Myelo... Myelodysplasia Myelomonocytic | Lonafarnib Placebo | 18 Years - | Merck Sharp & Dohme LLC | |
| Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma | NCT00761722 | Acute Myeloid L... Myelodysplastic... Lymphoma Multiple Myelom... Leukemia, Myelo... | azacitidine | 18 Years - | Celgene | |
| Volasertib in Combination With Azacitidine in Japanese Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia | NCT02201329 | Myelodysplastic... Leukemia, Myelo... | Azacitidine Volasertib | 20 Years - 80 Years | Boehringer Ingelheim | |
| Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) | NCT04266301 | Myelodysplastic... Leukemia, Myelo... | Sabatolimab Azacitidine Placebo | 18 Years - | Novartis | |
| Myeloproliferative Neoplasms (MPNs) Patient Registry | NCT02760238 | Primary Myelofi... Polycythemia Ve... Essential Throm... Mastocytosis Leukemia, Myelo... Leukemia, Myelo... Chronic Eosinop... Myelodysplastic... Neoplasms Leukemia, Myelo... | Observational | - | University Health Network, Toronto | |
| Sorafenib in Myelodysplastic Syndrome | NCT00510289 | Myelodysplastic... Leukemia, Myelo... | Sorafenib | 18 Years - | Duke University | |
| Efficacy Study of Revlimid® and Low Dose Continuously Administered Melphalan to Treat High Risk MDS | NCT00744536 | Myelodysplastic... Leukemia, Myelo... Angiogenesis | Lenalidomide an... | 18 Years - | Sunnybrook Health Sciences Centre | |
| Phase I Dose Escalation Trial of Volasertib in Combination With Azacitidine in Patients With MDS or CMML | NCT01957644 | Myelodysplastic... Leukemia, Myelo... | Azacitidine Volasertib | 18 Years - | Boehringer Ingelheim | |
| Azacitidine, Lenalidomide and DLI as Salvage Therapy for MDS, CMML and sAML Relapsing After Allo-HSCT | NCT02472691 | Leukemia, Myelo... Myelodysplastic... Leukemia, Myelo... | Lenalidomide Azacitidine Donor Lymphocyt... | 18 Years - 99 Years | Heinrich-Heine University, Duesseldorf | |
| A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes | NCT02841540 | Leukemia, Myelo... Myelodysplastic... Leukemia, Myelo... | H3B-8800 (RVT-2... | 18 Years - | Hemavant Sciences GmbH | |
| A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT) | NCT04264806 | Myelodysplastic... Leukemia, Myelo... | Azacitidine Cusatuzumab | 18 Years - | Janssen Research & Development, LLC | |
| Volasertib in Combination With Azacitidine in Japanese Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia | NCT02201329 | Myelodysplastic... Leukemia, Myelo... | Azacitidine Volasertib | 20 Years - 80 Years | Boehringer Ingelheim | |
| Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) | NCT03268954 | Myelodysplastic... Leukemia, Myelo... Leukemia, Myelo... | Azacitidine Pevonedistat | 18 Years - | Takeda |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
